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Abstract Boar spermadhesins are a group of seminal plasma, 
heparin-binding proteins which appear to be involved in sperm 
capacitation and gamete interaction. Using a proteolytic protec- 
tion assay we have identified regions of AQN-I,  AQN-3, PSP-I 
and AWN which remain attached to a heparin-Sepharose column 
following in-column digestion of bound spermadhesins with chy- 
motrypsin and elastase. In addition, the complete amino acid 
sequence of spermadhesin AWN was synthesized as overlapping 
peptides, and their ability to bind to a heparin-Sepharose column 
and to inhibit the interaction of soluble heparin with purified 
ELISA plate-coated AWN was tested. Both approaches gave 
similar results and as a whole showed that different regions of 
AWN may converge in its tertiary structure to form a composite 
heparin-binding site. The conformational heparin-binding surface 
resides on the GFCC'C" face of the proposed structural model 
for AWN and is in an opposite location to the carbohydrate- 
binding region of the spermadhesin. 
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I. Introduction 
Heparins are linear strongly acidic glucosaminoglycans com- 
posed of repeating units of o-glucosamine and hexuronic acid 
residues ubstituted with O-sulphates and N-sulphonates pro- 
duced by most animal cells [1]. Heparin and heparan sulphate 
glycosaminoglycans (GAGs) bind to a wide variety of physio- 
logically and developmentally relevant cell surface-associated, 
secreted, and extracellular matrix proteins, and this interaction 
appears to have important roles in diverse biological processes 
[2]. Heparin and heparan sulphate GAGs exert heir effects by 
modulating the activity of proteins to which they bind. The list 
of proteins with GAG-binding properties implicated in their 
biological roles is steadily increasing, and includes enzymes, 
enzyme inhibitors, extracellular matrix proteins, viral coat 
glycoproteins, blood coagulation factors, chemokines, growth 
factors, lectins, cell adhesion molecules, etc. [2]. 
Heparin-like GAGs secreted by the epithelium of the female 
reproductive tract, particularly at high concentration during 
the follicular phase of the estrous cycle, have been shown to 
invoke sperm capacitation i a number of mammalian species 
[3], and the effects of GAGs appear to be mediated by seminal 
plasma heparin-binding proteins which coat the sperm surface 
at ejaculation [4]. 
*Corresponding author. Fax: (49) (511) 953 8504. 
The major heparin-binding proteins (HBPs) of several do- 
mestic mammalian species have been thoroughly investigated. 
The HBPs of bull and stallion seminal plasma, termed PDC- 
109, BSP-A3, and BSP-30K, and HSP-1 and HSP-2, respec- 
tively, are polypeptides with 109-121 amino acid residues made 
up of one or more 13-15-residue O-glycosylated N-terminal 
repeats followed by two tandemly arranged omains each shar- 
ing the consensus sequence of fibronectin type-II modules (see 
[5] and references therein). The heparin-binding proteins of 
boar seminal plasma belong to another protein family, called 
spermadhesins [6], whose members are structurally unrelated 
to the bovine and equine HBPs. Boar spermadhesins (AQN-1, 
AQN-3, PSP-I and AWN) are a group of 14-16 kDa seminal 
plasma and sperm-associated l ctins [7], which are thought o 
play a major role in sperm capacitation [8] and gamete interac- 
tion [9]. 
The species-specific modulation exert by different heparin- 
binding proteins on sperm physiology may depend on how they 
interact simultaneously with GAGs ligands and sperm surface 
moieties. Bovine seminal plasma heparin-binding proteins have 
been shown to possess affinity for phosphorylcholine, suggest- 
ing a manner by which they become attached to the sperm 
surface [10]. Boar spermadhesins, depending on their aggrega- 
tion state, may bind to the sperm surface via phosphoryletha- 
nolamine-containing lipids or become coated as an aggregated 
coating material [11]. The aim of this study was the character- 
ization of molecular determinants of boar spermadhesins for 
binding heparin. 
2. Materials and methods 
Freshly ejaculated boar sperm was collected with an artificial vagina. 
Spermatozoa and seminal plasma were separated by centrifugation at 
12,000 × g for 15 min. 100 ml seminal plasma were dialyzed overnight 
against 50 mM Tris-HC1, 150 mM NaC1, 5 mM EDTA 0.025% sodium 
azide, pH 7.4 (TBS), and fractionated by affinity chromatography on 
a heparin-Sepharose CL-6B column (16 x 3 cm) (Pharmacia) equili- 
brated in the same buffer. The column was washed until the absorbance 
of the eluate at 280 nm reached baseline level. For proteolysis of the 
bound material, the column was recycled overnight at 23°C with 0.1 
mg/ml of either porcine pancreatic ~-chymotrypsin (EC 3.4.21.1) or 
elastase (3.4.21.36) (Sigma) in TBS. After washing, bound peptides were 
recovered eluting with TBS containing 1 M NaC1, and separated by 
reversed-phase HPLC on a Lichrospher RP100 C18 column (0.4 x 25 
cm, 5 pm particle size) (Merck) eluted at 1 ml/min with a gradient of 
0.1% (v/v) trifluoroacetic acid in water (solution A) and acetonitrile 
(solution B) as follows: isocratically with 5% solution B for 5 min, 
followed by 5% to 25% solution B for 80 min, and 25% to 70% solution 
B for 30 min. 
Peptides were characterized by N-terminal mino acid sequence anal- 
ysis using an Applied Biosystems 477A/120A sequencer, and amino 
acid analysis using an Alpha Plus (Pharmacia) amino acid analyzer 
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after sample hydrolysis with 6 M HCI for 24 h at 110°C in evacuated 
and sealed ampules. Peptide sequences were aligned in the amino acid 
sequences ofAWN [12], PSP-I [13,14], AQN-1 [15], AQN-3 [16], and 
seminal plasma trypsin inhibitor [17]. 
The following overlapping peptides, which cover the complete amino 
acid sequence ofporcine spermadhesin AWN (133 residues) [12], were 
synthesized using a standard Fmoc-protocol [18], using preloaded p- 
alkoxybenzyl alcohol resins or a Rink-amide resin (peptide P10), on a 
SMPS 350 automated multiple peptide synthesizer (Zinsser, Frankfurt) 
equipped with a 48-syringe synthesis block (Multisyntech, Bochum): 
P1, IAWNRRSRSAGGVLRDIS; P2, 13LRDPPGKIFNSDGPQ27; P3, 
25GPQKDAVWTIKVKPHF4°; P4, 37KPHFHVVLAIPPLNL51; P5, 
46AIPPLNLSAGKEYVE59; P6, 53AGKEYVELLDGLDG63; P7, 61L- 
DGPPGSEIIGKIAG75; P8, 73IAGGISLVFRSSSNI87; P9, SIFRSSSN- 
IATIKRLRT95; P10, 89TIKRLRTSGHRASPFI°3; P11, 97GHRASPF- 
HIYYYADPIII; P12, 1°gADPEGPLPFPYFERQI23; and P13, IIgYFE- 
RQTIIATEKNIP 133. The four cysteine residues of AWN (positions 9, 
30, 53, and 74), which form two disulphide bridges between earest 
neighbor residues [12] were substituted by alanine. 
For testing the ability of synthetic peptides P1-PI 2 to bind heparin, 
the peptides (1 mg/ml in TBS) were chromatographed on a heparin- 
Sepharose CL-6B column (1 x 10 cm) using an FPLC equipment (Phar- 
macia) and the same chromatographic conditions as above. The non- 
bound and bound fractions were characterized by reversed-phase 
HPLC on a Lichrospher RP100 C 18 column (0.4 x 25 cm, 5/2m particle 
size) (Merck) eluted at 1 ml/min with a gradient of 0.1% (v/v) tri- 
fluoroacetic acid in water (solution A) and acetonitrile (solution B) 
isocratically with 5% solution B for 5 min, followed by 5% to 30% 
solution B for 50 min, and 30% to 70% solution B for 20 min. Isolated 
peptides were identified by amino acid analysis. 
The ability of synthetic peptides P1 P10 to inhibit the binding of 
biotinylated heparin to purified AWN-1 was assessed using an enzyme- 
linked immunosorbent assay (ELISA). To this end, 1 /2g of AWN 
(purified as described in ref. [6]) in 100/21 50 mM Na2CO3/NaHCO3 
buffer, pH 9.5, were coated overnight at 40C onto ELISA plate wells. 
After blocking with TBS buffer containing 5% (w/v) bovine serum 
albumin (BSA) for 2 h at 37°C, the immobilized proteins were incu- 
bated with 100/21 of solutions containing 60 ng biotinylated heparin 
preincubated for 1 h at 37°C with increasing concentrations (0.1-100 
nmoles) of a given synthetic peptide in TBS. After 3 x washing with TBS 
containing 0.5% (w/v) BSA, samples were incubated with 100/21 strep- 
tavidin-peroxidase (1:4000, v/v) in washing buffer, washed 3 times, 
and developed with 100/21/well of2 mg/ml o-phenylendiamine in 20 mM 
citric acid, 50 mM NaH2PO 4buffer, pH 5, containing 70/21 H202 
(30%)/100 ml. The color developed was measured at 492 nm with an 
automated micro-ELISA reader (ICN). 
3. RESULTS 
3.1. Location of heparin-b&ding regions using a proteolytic 
protection approach 
As a first approach for characterizing heparin-binding re- 
gions of boar spermadhesins, seminal plasma was fractionated 
by affinity chromatography on heparin-Sepharose and the 
bound proteins (a mixture of AQN-1, AQN-3, PSP-I, and 
AWN [6,14]) were proteolytic degraded with either ct-chymo- 
trypsin or elastase. The rationale behind this approach was that 
those protein regions interacting with heparin should be pro- 
tected from proteolysis and would remain bound to the affinity 
matrix. 
Table 1 shows the results obtained and Fig. 1 the location of 
the chymotryptic (C-) and elastase-derived (E-) heparin-bound 
fragments within the amino acid sequences of boar spermad- 
hesins. Degradation with chymotrypsin yielded 11 fragments, 
which mapped to three different regions of the parent proteins. 
Fragments C-3, C-10, C-l, and C-7 were derived from the 
N-terminal region of AQN-I, PSP-I, AQN-3, and AWN, re- 
spectively. Fragments C-10 and C-7 contained each two di- 
sulphide-bonded peptides, whereas C-3 and C-1 corresponded 
to the loop region formed by the conserved isulphide bridge 
between the first two cysteines of the proteins [12,13,15,16]. 
Fragments C-4, C-8, and C-11, contained each two peptides 
disulphide-bonded by the second conserved cystine of spermad- 
hesins AQN-1 [15], PSP-I [13], and AWN [12]. Peptide C-5 
corresponded to a region of AQN-3 which aligns with the 
C-terminal part of peptides contained in C-4, C-8, and C-11 
(Fig. 1). Finally, fraction C-2 contained two peptides encom- 
passing a highly homologous, tyrosine-rich region at the C- 
terminal part of AQN-1 and AWN. 
When heparin-bound seminal plasma proteins were degraded 
with elastase, only one peptide corresponding to a sperm- 
adhesin molecule (E-l, AWN 101-109) (Table 1) was found. 
This fragment contained the sequence found in C-2 flanked by 
several other residues at the N- and C-termini (Fig. 1). Other 
heparin-bound fragments corresponded to polypeptide 
stretches of a seminal plasma acrosin inhibitor [17] (Table 1). 
3.2. Analysis of the heparin-binding capability and ,4 WN- 
heparin-binding inhibitory activity of synthetic peptides 
To narrow down the heparin-binding domain of AWN, the 
complete amino acid sequence of the protein was synthesized 
as 11-15-mer overlapping peptides. When these peptides were 
probed for their capability to bind to heparin-Sepharose (either 
individually or as a mixture) it was found that peptides P2, P5, 
P6, P7, P12, and P13 eluted with the flow-through fraction; 
peptides P3, P4, and P11 were retarded in the column and 
eluted under isocratic onditions with 4-5 column volumes, and 
peptides P1, P8, P9, and P10 bound to the affinity matrix and 
were eluted with 1 M NaCI. Alignment of these peptides with 
the AWN structure is shown in Fig. 1. 
The ability of synthetic peptides to interfere with the binding 
of biotinylated heparin to purified AWN was tested using com- 
petitive ELISA. Only peptides P8, P9, P10, and P11 inhibited 
AWN-heparin interaction i  a concentration-dependent ma - 
Table 1 
Characterization f proteolytic products which remained bound to 
heparin-Sepharose after digestion of heparin-bound boar seminal 
plasma proteins with ct-chymotrypsin (C-) or elastase (E-) 
Peptide N-terminal amino acid sequence Corresponds to
C-I N Y S G W I S Y AQN-3  15-22 
C-2 D I Y Y Y AQN-1 106-108 
H I Y Y Y AWN 106-108 
C-3 R I S T Y E G P K T D AQN- I  19-29 
C-4 A C G K E Y AQN- I  52-57 
N Y G K L C S G I G L AQN- I  69-79 
C-5 T V Y Q S S AQN-3  79-84 
C-6 T Y Q S S S N A L AQN- I  80-88 
C-7 AWNRRSRSCGGVL AWN 1-13 
N S D G P Q K D C V W AWN 22-32 
C-8 N L T C G K E Y PSP-I 47-54 
C EGL  S I LNRG S S GM PSP-I 71-79 
C-9 R D L S G R I S T Y E G P K T AQN- I  14-28 
C-10 H A C G G R L PSP-I 4-10 
T E C V W PSP-I 25-29 
C-I 1 S C G K E Y AWN 52-57 
C G G I S LV  F R S S S N I AWN 74-87 
E-1 S P F H I Y Y Y A AWN 101-109 
E-2 KKTRKE PDXD AI 4-17 
H L F F X T R E M AI 18-69 
E-3 A R S K K T R K E P AI  1-69 
Peptides were aligned in the amino acid sequences of AWN [12], PSP-I 
[13,14], AQN-I [15], AQN-3 [16], and acrosin inhibitor (AI) [17]. 
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AQN- I  : 
PSP- I  : 
AQN-3  • 
AWN : 
1 i0 20 30 40 
i .............................................. S -S  ................................ I 
A Q N K G P H K C G G V L R D L S G R I  S T Y E G P K T D C  IWT I L A K P G S  
I C-3 i 
L D Y H A C G G R L T D D Y G T I  F T Y K G P K T E C V W T L Q V D P K Y  
I C-10 I f - - c -10- -1  
A Q N K G S  D D C G G F L K N Y S  GWI  S Y Y K A L T T N C V W T  I E M K P G H  
I C - l - - i  
A W N R R S R S C G G V L R D P P G K I F N S D G P Q K D C V W T  I K V K P H F  
I C-7 q I C - 7 - - 1  
I - -  P1 (B) I I P3 (R) I 
I P2(~)  I I -P4(R) -  
AQN- I  : 
PSP- I  : 
AQN-3  : 
AWN : 
41 50 60 70 80 
f . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  $ -$  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  i 
R V F V A I P Y L N L A C G K E Y V E V Q D G L P G A G N Y G K L C S  G IGLT  
f c -4  - - i  t. c -4  It- 
K L L V S  I P T L N L  T C G K E  Y V E V L E  G A P G S  K S L G K F C E  GLS  IL  
I - -  c-8 - - I  I - -  C-8 - -  
K I  I L Q I L P L N L T C G K E Y L E V R D Q R A G P D N F L K V C G G T G F V  
I-- 
H V V L A I  P P L N L S C G K E Y V E L L D G P P G S E  I I G K I C G G I  SLV 
I C-l l  - - I  I - -  C-l l  - -  
- - P 4  [ I - - P 6  (NB) i I . - -P8  (B)+----- 
I P5 (NB) I I P7 (NB) [ 
AQN- I  : 
PSP- I  : 
AQN-3  : 
AWN : 
81 90 i00 ii0 120 
YQS S S NALS I KY  S R T A G H  SAS S FD I Y Y Y G D S  
- - c - 6 - - I  I - - c -2  - - I  
NRGS S - G M T V K Y K R D S  G H P A S  PYE  I I F L R D S Q G  
I 
YQS S X N V A T V K Y  S RDS H H P A S  S F N V Y F Y G  I P Q G A K A  
- -C-5--1 
FRS S S N I A T I K R L R T S G H R A S P F H  I Y Y Y A D P E G P L P F P Y F  
- -C - I I - - [  I - -C -2 - - I  
; g - l - - I  
- -P8  - - I  I- PI0 (B)+ [ I PI2 (~) - -  
i P9 (B)+ I i PII  (R)+ 1 I - -  
121 130 
AWN : E R Q T I I A T E K N I P 
PI3 (NB) I 
Fig. 1. Alignment of the amino acid sequences of boar spermadhesins AQN-1 [15], PSP-I [13,14], AQN-3 [16], and AWN [12] showing the chymotryptic 
(C-) and elastase-derived (E-) fragments obtained by in situ proteolysis of heparin-bound seminal plasma proteins. The location of overlapping 
synthetic peptides PI-P13 of AWN employed to determine heparin-binding capability and AWN-heparin-binding inhibitory activity are shown 
beneath the AWN sequence. NB, R, and B, denote those peptides which were nonbound, retarded, or bound in the heparin-Sepharose column. 
+, peptides with AWN-heparin-inhibitory activity. 
ner (Fig. 2) with IC5o values of 2.5, 1.4, 5.5, and 6.0 /LM, 
respectively. 
4.  D iscuss ion  
The results on in situ-degradation of heparin-Sepharose- 
bound boar seminal plasma proteins summarized in Table 1 
and Fig. 1 indicate that discrete regions of spermadhesins 
AQN-1, PSP-I, AQN-3, and AWN may converge, as a result 
of the tertiary structure of the proteins, to form a composite 
heparin-binding domain. Except for C-2 (and E-l) which are 
tyrosine-rich peptides, all other heparin-bound fragments con- 
tain one or more basic residues (Fig. 1). This is in agreement 
with recent studies showing that glycosaminoglycan-binding 
sites are typically extended clusters of positively charged amino 
acids distributed along the surface of a protein, or in a shallow 
groove [19] termed a 'cationic radle' [20]. In addition, aromatic 
residues have been shown to contribute to the protein-heparin 
binding affinity [21]. It is therefore conceivable that tyrosine 
interacts with heparin by formation of hydrogen bonds between 
its hydroxyl group and the secondary alcoholic groups of the 
heparin carbohydrate units, and through a stacking interaction 
between the aromatic ring of tyrosine and the carbohydrate 
moieties of heparin. Such interaction has been observed in 
crystal structures of galactose-binding lectins [22]. However, 
there is no example of a GAG-protein complex determined by 
X-ray crystallography or NMR methods and current concepts 
about protein-GAG interactions have been derived by com- 
puter-assisted modelling studies (reviewed in [2,19]). 
The heparin-bound fragments were largely derived from to- 
pologically equivalent stretches within the amino acid se- 
quences of AQN-1, PSPq, AQN-3, and AWN comprising re- 
gions around the two conserved isulphide bridges and at the 
C-terminal part of the molecules (Fig. 1). However, differences 
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were also observed. Hence, while AQN-1 and AQN-3 con- 
tained heparin-bound peptides mapping to the loop region be- 
tween the first two cysteines (C-3 and C-l, respectively) (Table 
1, Fig. 1), PSP-I and AWN heparin-bound fragments C-10 and 
C-7, respectively, each contained two disulphide-bonded pep- 
tides. The amino acid sequences AQN-1 ~7SGRISTy23 and 
AQN-3 14KNYSGWISY22 of heparin-bound peptides C-3 and 
C-1, respectively, display similarity with the sequence stretches 
99RGRISCTl°5 and 189SGRITCTI95 involved in the binding of 
heparin to fibronectin [23]. Furthermore, similarly to AQN-1 
and PSP-I, the fibronectin sequences are located in disulphide- 
bonded loops [24]. On the other hand, the amino acid sequence 
of AWN 4RRSRS8 contained in peptide C-7 (Table 1, Fig. 1) 
resembles the consensus equence XBBXBX (B, basic amino 
acid) found in the heparin-binding regions of many diverse 
proteins [25]. This evidence suggests that the topology of the 
heparin-binding domain may not be absolutely conserved in 
different spermadhesins. 
AWN is the most thoroughly investigated spermadhesin mol- 
ecule regarding its ligand-binding capabilities and relative loca- 
tion of active sites (reviewed in [7]). We choose therefore AWN 
to narrow down the architecture of its heparin-binding do- 
main(s). To this end, the heparin-binding capability and AWN- 
heparin-binding inhibitory activity of synthetic peptides (P1- 
P13, Fig. 1), which cover the complete amino acid sequence of 
AWN, were investigated. Peptides of both the N- and the C- 
terminal regions of AWN retained heparin-binding activity. 
Furthermore, peptides P8, P9, P10, and Pl l  (encompassing 
residues 73 110) competed with AWN for binding to heparin 
(Fig. 2). These region of AWN which includes the heparin- 
bound proteolytic fragments C-11, C-2, and E-1 (Table 1, Fig. 
1), may therefore contain essential residues for heparin-bind- 
ing. The region 73 110 spansfl-strands F and G and the loops 
connecting fl-strands E-F and F-G in the proposed structural 
model for AWN [26,27] shown in Fig. 3, and, therefore, would 
be located on the same face of the molecule. On the other hand, 
the fact that peptides P1, P3 and P4 bound to heparin-Sepha- 
rose or were retarded by the affinity matrix, but did not inter- 
fere with AWN-heparin interaction, might suggest that AWN 
Zl I 
0 
0 2 4 
nmol pepfide 
Fig. 2. AWN-heparin-inhibitory activity of synthetic peptides derived 
from the AWN amino acid sequence. =,P1, P2, P3, P4, Ph, P6, P7, P12, 
P13; A, Pll; e, P9; o, P8; z~, P10. 
"~A 
Fig. 3. Proposed structural model of AWN [25,26] schematically depict- 
ing the location of the primary (on strands F and G and loop regions 
between strands E-F and F-G) and secondary (polypeptide stretch 4-8 
and N-terminal part of strand A) heparin-binding regions (black filled 
regions) characterized in this study. The proposed topological relation 
of the composite heparin-binding domain to the carbohydrate-binding 
region (stripped circle) on the GFCC'C" face of the molecule ishigh- 
lighted. N and C, N- and C-termini, respectively. The position of di- 
sulphide bridges between cysteine residues (Cys) 9-30 and 53-73 [12] 
is shown. 
possess an additional, secondary heparin-binding region. This 
region would comprise the polypeptide chain 4-8, the N-termi- 
nal part offl-strand A, and the loop between ,B-strands C and 
C' (Fig. 3). The loop connecting strands C-C' would lay on the 
GFCC'C" face of the AWN model while the N-terminal stretch 
might not be constraint in a fixed conformation. It is notewor- 
thy that similar to our results concerning AWN 4RRSR8, the 
RRAR sequence, when present in a synthetic peptide, has been 
shown to have weak affinity for heparin [28,29]. Furthermore, 
this same RRAR sequence xists in the carboxylterminal lobe 
of lactoferrin where it is not functional as a GAG-binding site 
[30]. These results together with recent mutagenesis studies on 
fibronectin module III-13 have point out that the BBXB con- 
sensus sequence by itself has little affinity for heparin even 
when presented in the context of a folded domain [31]. 
As a whole, the results obtained by proteolytic protection 
assay and synthetic peptide approaches are consistent and com- 
plement each other. Noteworthy, the heparin-binding domain 
of AWN appears to be located in the same face where the 
carbohydrate-binding surface has been mapped [13,27,32] 
(schematically depicted in Fig. 3). If the structural model of 
AWN turns to be correct, the heparin-binding region would 
run in NW-SE direction of the GFCC'C" face (Fig. 3) while the 
carbohydrate-binding re ion would be located on the CC'C" 
corner. This may provide a structural basis for the observation 
that heparin inhibits the binding of carbohydrate-ligands (zona 
pellucida) to AWN [6] by interacting with a region different 
than the oligosaccharide r cognition domain [27,32]. 
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